The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients by Tiffin-Richards, Frances E. et al.
The Montreal Cognitive Assessment (MoCA) - A Sensitive
Screening Instrument for Detecting Cognitive
Impairment in Chronic Hemodialysis Patients
Frances E. Tiffin-Richards1,2, Ana S. Costa1,2, Bernhard Holschbach3, Rolf D. Frank4, Athina Vassiliadou5,
Thilo Kru¨ger6, Karl Kuckuck1,2, Theresa Gross6,7, Frank Eitner6,8, Ju¨rgen Floege6, Jo¨rg B. Schulz1,2,
Kathrin Reetz1,2,9*
1Department of Neurology, RWTH Aachen University Hospital, Aachen, Germany, 2 Ju¨lich Aachen Research Alliance (JARA) – Translational Brain Medicine, Aachen and
Ju¨lich, Germany, 3 KfH Curatorship for Dialysis and Kidney Transplant e.V., KfH-Nephrology Center, Stolberg, Germany, 4Department of Internal Medicine, St.-Antonius-
Hospital Eschweiler, Eschweiler, Germany, 5Dialysis Center Aachen, Dialysis Center, Aachen, Germany, 6Division of Nephrology and Clinical Immunology, RWTH Aachen
University, Aachen, Germany, 7Department of Internal Medicine, Dresden-Friedreichstadt Hospital, Dresden, Germany, 8 Bayer Pharma AG, Global Drug Development,
Kidney Diseases Research, Wuppertal, Germany, 9 Institute of Neuroscience and Medicine (INM-4), Research Center Ju¨lich GmbH, Ju¨lich, Germany
Abstract
Background: Chronic kidney disease (CKD) patients undergoing hemodialysis (HD) therapy have an increased risk of
developing cognitive impairment and dementia, which are known relevant factors in disease prognosis and therapeutic
success, but still lack adequate screening in clinical routine. We evaluated the Montreal Cognitive Assessment (MoCA) for
suitability in assessing cognitive performance in HD patients in comparison to the commonly used Mini-Mental State
Examination (MMSE) and a detailed neuropsychological test battery, used as gold standard.
Methods: 43 HD patients and 42 healthy controls with an average age of 58 years, were assessed with the MoCA, the MMSE
and a detailed neuropsychological test battery, covering the domains of memory, attention, language, visuospatial and
executive functions. Composite scores were created for comparison of cognitive domains and test results were analyzed
using Spearman’s correlation and linear regression. Cognitive dysfunction was defined using z-score values and predictive
values were calculated. Sensitivity and specificity of the MoCA were determined using receiver operating characteristic
(ROC) analysis.
Results: HD patients performed worse in all cognitive domains, especially in memory recall and executive functions. The
MoCA correlated well with the detailed test battery and identified patients with cognitive impairment with a sensitivity of
76.7% and specificity of 78.6% for a cut-off value of #24 out of 30 points. In the detailed assessment executive functions
accounted significantly for performance in the MoCA. The MMSE only discriminated weakly between groups.
Conclusions: The MoCA represents a suitable cognitive screening tool for hemodialysis patients, demonstrating good
sensitivity and specificity levels, and covering executive functions, which appear to play an important role in cognitive
performance of HD patients.
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Introduction
The association of cognitive impairment and a higher incidence
of dementia in patients with chronic kidney disease (CKD) has
been increasingly acknowledged over the last few years [1–3] and
represents an important issue in an already vulnerable population.
The prevalence of cognitive impairment in chronic hemodialysis
(HD) patients has been estimated at 30–80% [4–7]. In addition to
being associated with cerebrovascular disease and potentially other
types of brain injury [8], cognitive impairment may jeopardize
treatment adherence by affecting the efficiency of every-day tasks,
including correct medication and dietary rules [9]. Moreover,
cognitive impairment is a significant predictor of mortality in HD
patients [5].
The call for early detection of cognitive impairment in patients
with CKD has yet to be translated to every-day clinical practice.
The necessity has, however, been voiced in earlier studies and the
use of short and easy-to-apply cognitive screening tools has been
suggested [5,10]. The Montreal Cognitive Assessment (MoCA)
[11] is a screening test for cognitive impairment that covers major
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cognitive domains including episodic memory, language, atten-
tion, orientation, visuospatial ability and executive functions, while
remaining brief and easy to administer. It is generally considered
superior to the well-established Mini-Mental State Examination
(MMSE) screening test [12,13], since the MoCA not only assesses
executive functioning, which may be particularly important in the
CKD population [14,15], but also presents a higher sensitivity for
mild cognitive impairment. Accordingly, the MoCA has been
evaluated and found to be an adequate screening tool in various
clinical populations, e.g. Alzheimer’s dementia (AD) [16], cerebral
small vessel disease [17], and other medical conditions such as
cardiovascular disease [18], as well as being able to discriminate
between mild cognitive impairment and elderly controls [19].
Recently, the MoCA was also recommended as a standardized
approach to cognitive assessment in patients undergoing HD [20].
Therefore our primary goal was to further evaluate the MoCA as a
brief screening tool for cognitive impairment in HD patients in
comparison to a comprehensive cognitive testing. To achieve this,
the ability to distinguish between HD patients with and without
cognitive impairment, the sensitivity, specificity and predictive
values of the MoCA were assessed. Additionally, psychometric
criteria such as concurrent and criterion validity of performance
on the MoCA, a comprehensive neuropsychological test battery
and the standard brief cognitive screening test MMSE were
evaluated.
Subjects and Methods
Ethics Statement
The research project was carried out in accordance with the
latest version of the Declaration of Helsinki and approved by the
ethics committee of the Medical Faculty of the RWTH Aachen
University in Germany (EK 179/11). All participants gave
informed, written consent before participating.
Study population
Between February 2012 and March 2013, forty-eight patients
on hemodialysis treatment were recruited from the Division of
Nephrology of the RWTH Aachen University Hospital in
Germany and three community based dialysis centers in the
Aachen region. Forty-two matching healthy controls of varied
intellectual and educational level, but without specific experience
in neuropsychology, were recruited from the community and staff
of the RWTH Aachen University. All participants with a history of
neurological or psychiatric disease were excluded. In two cases of
severe visual or motor impairment, specific tasks were not
administered and therefore considered missing values. These cases
included one patient with residual eye sight of 30% due to diabetic
retinopathy and glaucoma and one patient with a disabilitating
hand tremor.
Clinical and demographic data
Medical history and demographic data were gained via self-
report and/or from medical records. Patients’ clinical data
included medical history, current medication, CKD etiology,
dialysis vintage, serum values of sodium, potassium, hemoglobin,
hematocrit, creatinine, pH value and blood sugar and were
obtained from routine clinical blood samples taken at the
beginning of each dialysis treatment. The duration of dialysis
treatment, ultrafiltration volume, pre-dialysis blood pressure values
and intradialytic hypotensive episodes, defined as systolic blood
pressure , 90 mmHg and/or diastolic blood pressure ,
50 mmHg, were collected from the dialysis protocols. Cardiovas-
cular risk factors, including nicotine consumption, body mass
index (BMI), serum cholesterol and high blood pressure were rated
using the SCORE risk charts of the European Society of
Cardiology [21] using the low risk chart for the German
population. Hypertension was defined as the prescription of
antihypertensive medication. Comorbidities were quantified using
the Charlson Comorbidity Index (CCI) [22] corrected for dialysis
[23], or age in the healthy control group [22].
Neuropsychological testing
The neuropsychological test battery was administered to all
subjects on a dialysis-free day by a psychologist or trained
assistants. It consisted of two cognitive screening tests, the MoCA
and the MMSE, as well as a detailed cognitive test battery that
evaluated memory, language, attention, visuospatial ability and
executive functions. As participants were partaking in a cross-
sectional observational study with a repeated-measures design
[24], previously validated alternate versions of the MoCA [25], as
well as from other tests, were used to avoid practice effects. For all
patients and controls the same order of test administration was
used. The alternate versions of tests were contra-balanced in a
pseudo-randomized order. Although all patients and controls
underwent two rounds of testing, only the data of the first
assessment was used in the current analyses and therefore not all
participants completed the exact same version of all tests. Testing
was performed in a quiet room with a low distraction level, but in
cases of reduced mobility, testing was also performed in patients’
hospital rooms. For the order of test administration, view List S1 in
File S1.
The MoCA [11] is a brief screening tool assessing visuospatial
and executive functions, attention, short-term memory, language
and orientation, has been translated and adapted into several
languages and is available freely on the Internet (http://www.
mocatest.org). It includes tasks such as trail making test – part B,
cube copying, clock drawing, naming, digit span backwards and
forwards, serial subtraction, selective attention, sentence repeti-
tion, phonemic word fluency, verbal abstraction, a 5-word
learning and delayed recall task, and spatial and temporal
orientation. Completion time is approximately 10 to 15 minutes
and a maximum of 30 points can be obtained.
The ability of the MoCA to screen for cognitive impairment in
HD patients was to be evaluated through the comparison to a well-
known screening test, the MMSE, and a detailed neuropsycho-
logical test battery. Given that our emphasis lay on the evaluation
of the MoCA, detailed group analyses, such as correlation analysis,
were not performed with the MMSE and the detailed neuropsy-
chological battery.
The MMSE is a ten-minute screening test including questions to
spatial and temporal orientation, immediate and delayed recall,
language ability and oral command comprehension, serial
subtraction and tasks to visuospatial ability. Here the German
adaptation was used for all participants [12].
A more detailed analysis of the cognitive domains and
psychometric characteristics, such as sensitivity, specificity and
concurrent validity, of the MoCA was achieved by comparison to
a detailed neuropsychological test battery. In the detailed
neuropsychological test battery, verbal memory was examined
using the California Verbal Learning Test (CVLT) [26], a word
list recall task, and non-verbal memory was assessed with the
Medical College of Georgia Complex Figures (MCGCF) test [27].
Attention was evaluated through a computer-based cued and non-
cued reaction time (phasic and intrinsic alertness) task [28] and
digit span forwards. Processing speed and executive functions were
assessed using the Trail Making Task (TMT) forms A and B [29],
phonemic and semantic word fluency [30], digit span backwards
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[31], and the interference task of the Stroop test [32]. The Boston
Naming Test [33] gave information on overall language process-
ing ability. Visuospatial abilities were tested with the copying task
of the MCGCF and the Incomplete Letters subtest of the Visual
Object and Space Perception (VOSP) test [34], which also served
to identify individuals with visual impediments that could hinder
further testing. We also included the Epworth Sleepiness Scale
(ESS) [35] to measure daytime sleepiness. Subjective fatigue level
was evaluated through a 10-point scale (0 = no fatigue to
10 = worst imaginable fatigue) adapted from the Brief Fatigue
Inventory [36]. Depression and anxiety were quantified with the
Hospital Anxiety and Depression Scale (HADS) [37]. For further
detail on individual tests, see Table S1 in File S1.
Statistical analysis
Data analysis was performed using Microsoft Excel 2010, IBM
SPSS Statistics 20 for Windows and MedCalc Software Version
12.5.0. The distribution of the collected data was determined using
the Kolmogorov-Smirnov test. Due to heterogeneous normal and
non-normal distribution of data, non-parametric tests were used
and all test results are presented with median and interquartile
ranges for better comparability. Demographic data is presented
according to the distribution of the respective data. Differences,
and respective effect sizes (r), between patients and controls
regarding demographic and clinical data, as well as the
neuropsychological test scores, were computed using the non-
parametric Mann-Whitney-U test with Bonferroni correction for
multiple testing. The interpretation of effect sizes followed Cohen’s
proposal for r as small at 0.10–0.29, medium at 0.30–0.49 and
large at .0.50 [38]. Correlation analyses were carried out using
Spearman’s rank correlation coefficient rho (rs). We calculated
standard z-scores for each cognitive test, using the healthy control
group as the reference group and without replacing missing values.
Based on the median of z-scores of the individual tests, we
calculated composite scores for each cognitive domain – memory,
attention, language, visuospatial, executive functions – as well as
two overall composite scores. The overall composite scores were
an executive composite score, including the executive functions
and attention tasks, and a non-executive composite score
comprising of the language, visuospatial and memory tasks. The
same procedure was used to create composite scores of the
cognitive domains of the MoCA. For further analysis, cognitive
dysfunction was defined using z-score values. Mild cognitive
impairment was classified as z-scores one to two standard
deviation (SD) below the norm and severe cognitive impairment
as more than two SD below the norm in $2 neuropsychological
tests [5,9]. To examine concurrent validity between the MoCA
total scores and the test battery overall composite scores, a
bivariate linear regression model with the MoCA as the dependent
variable and the composite scores as the independent variables was
calculated. The raw total scores of the MoCA were used without
education correction [16], and age, years of education, depression
and fatigue levels were added as covariates [2]. To establish the
discriminative validity of the MoCA in identifying patients with
and without cognitive impairment, sensitivity and specificity levels
were evaluated using the receiver operating curve (ROC) analysis
and the criteria for cognitive impairment as described above. The
cut-off score was determined based on maximal sensitivity and
specificity. Positive and Negative Predictive Values (PPV/NPV)
were calculated for the optimal cut-off value identified by the
ROC analysis.
Results
Characterization of the HD patient sample
Forty-three HD patients completed testing and were included in
the current analyses. Details of clinical and demographic data are
presented in Table 1. In comparison to the control group, HD
patients had a significantly higher rate of hypertension, diabetes
type 2, hypercholesterolemia and nicotine consumption, yet no
significant difference concerning BMI. Levels of fatigue and
sleepiness, as well as scores on the depression scale were higher in
the patient group. On average, patients had been on dialysis
treatment for 50 months and spent four hours on dialysis, three
times per week, with an average ultrafiltration volume of 1.2 liters.
The 10-year risk of a fatal cardiovascular disease lay at 3–4% [21]
while the CCI scoring system for HD patients presented a mean
10-year survival rate of 25% [23].
Performance on the MoCA and association with
demographic and clinical variables
HD patients achieved lower mean total scores in the MoCA
than the control group. The deficits were especially prominent in
the areas of executive functions, language ability and short-term
memory capacity (Figure 1). The most difficult tasks appeared to
be digit span backwards and forwards, phonemic word fluency,
sentence repetition, verbal abstraction and immediate and delayed
word recall (see Table S2 in File S1). No significant differences
could be identified between groups in respect to visuospatial tasks,
naming, level of attention (as tested in the letter cancellation and
number subtraction tasks) or temporal and spatial orientation.
In the patient group there was a negative association between
the MoCA total score and age (rs =2.38, p,.05), which was not
found in the control group. There was a positive association
(rs = .28, p,.01) between the MoCA and education. From the
association analysis between clinical variables and performance on
the MoCA, only the CCI score for dialysis patients correlated
negatively with the MoCA total scores (rs =2.53, p,.001),
indicating that patients with a higher comorbidity score achieved
lower results in the MoCA.
Performance on the detailed neuropsychological test
battery
In the detailed neuropsychological testing, patients performed
worse than the control group in all cognitive domains (Table 2).
Patient performance was worse in tasks such as immediate and
delayed verbal and visual memory, semantic and phonemic word
fluency, as well as performance on the TMT, reaction-timed
alertness and the Stroop interference task. Cognitive dysfunction
was identified in 29 patients (70%), whereby for 10 patients (24%)
cognitive dysfunction could be classified as mild cognitive
impairment and for 19 patients (46%) as severe cognitive
impairment.
Correlation analysis showed that the composite scores of the
MoCA and the test battery correlated in the domains of executive
functions (rs = .60, p,.001) and memory (rs = .53, p,.001),
whereas the attention, language and visuospatial composites
revealed no significant association. The MoCA and the MMSE
total scores showed a moderate positive correlation (rs = .54, p,
.001).
Association between the MoCA and the detailed
neuropsychological assessment
Linear regression analysis revealed that the composite score
including executive functions tasks explained 39% (b= 0.62,
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Table 1. Demographic and health characteristics.
Demographics Patients Controls pe)
Age 58.3613.9 57.9611.8 .96
Gender Male 52.1% (25) Male 47.6% (20) .67
Education (years) 12.0 (2.0) 13.0 (3.3) .01
Comorbidities
BMI 24.4 (6.7) 25.263.8 .71
Hypertension 83.3% (40) 33.3% (14) ,.001
Diabetes 45.8% (22) 4.8% (2) ,.001
Nicotine consumption 25.0% (12) 7.1% (3) .02
Hypercholesterolemia 31.3% (15) 0% ,.001
Cardiovascular Score (ESC - SCORE) 1.0 (4.0) - -
Charlson Comorbidity Index (CCI)a) 4.0 (3.0) - -
Hemodialysis
Dialysis Vintage (months) 36.0 (47.0) - -
Time on dialysis (hours) 4.0 (0.0) - -
Ultrafiltration volume (l) 1.2 (2.1) - -
Etiology of renal disease
Diabetic nephropathy 27.1% (13) - -
Glomerulonephritis and systemic diseases 27.1% (13) - -
Vascular (hypertensive) kidney disease 14.6% (7) - -
Other causesb) 12.5% (6) - -
Polycystic kidney disease 10.4% (5) - -
Unknown 8.3% (4) - -
Secondary diseases
Renal anemia 38.5% (20) - -
Secondary hyperparathyroidism 34.6% (18) - -
Renovascular hypertension 19.2% (10) - -
Kidney transplant in medical history 13.5% (7) - -
Medication
Antihypertensive Medication (total number) 3.0 (4.0) 0.0 (0.0) ,.001
ACE* inhibitors 37.2% (16) 7.1% (3) ,.001
Beta blockers 67.4% (29) 16.7% (7) ,.001
Calcium channel blockers 48.8% (21) 7.1% (3) ,.001
Angiotensin receptor blockers 20.9% (9) 4.8% (2) .03
Alpha-1 blockers 25.6% (11) 0% ,.001
Adrenergic alpha agonists 23.3% (10) 0% ,.001
Direct vasodilators 9.3% (4) 0% .04
Diuretics 46.5% (20) 4.8% (2) ,.001
Antidiabeticsc) 37.2% (16) 2.4% (1) ,.001
Thyroid drugs 30.2% (13) 7.1% (3) .01
Psychoactive drugsd) 23.3% (10) 0% .02
Analgesics 16.3% (7) 2.4% (1) .01
Glucocorticoids 25.6% (11) 0% ,.001
Notes. Values are presented as mean 6 SD for normally distributed continuous variables, median (interquartile range) for non-normally distributed continuous variables
and % (N) for percentages.
a) History of cerebral disease found in two cases;
b) Other causes include progression of acute kidney disease due to post-operative infections, urologic reflux diseases, analgesic medication;
c) Including oral antidiabetics and insuline therapie;
d) Psychoactive drugs include antipsychotics, antidepressants, anticonvulsives and drugs containing L-DOPA;
e) p-value of nonparametric Mann-Whitney-U test for independent samples;
* ACE =Angiotensin Converting Enzyme.
doi:10.1371/journal.pone.0106700.t001
Cognitive Screening in Hemodialysis Patients
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e106700
R2 = .39, p,.001) of the variance in the MoCA and the non-
executive functions composite score explained 34% (b= 0.58,
R2 = .34, p,.001). Together, executive and non-executive func-
tions accounted significantly for overall performance on the
MoCA (b= 0.42, R2 = .44, p,.001), while the covariates age
(b= 0.26, R2 = .07, p,.05) and education (b= 0.23, R2 = .05, p,
.05) only marginally affected variance in performance. Sleepiness
and fatigue did not show a significant effect on cognitive
performance, yet high scores on the depression scale had a mild
effect (b=20.36, R2 = .13, p,.001).
ROC analysis and predictive values
The ROC analysis disclosed an optimal cut-off for the MoCA
at #24 points (Table 3), with a sensitivity of 76.7%, specificity of
78.6% and an area under the curve (AUC) of 0.755 (95% CI,
0.602–0.872). In comparison, the MMSE only achieved a
sensitivity of 55.2%, and a specificity of 75.0%, and AUC of
0.701 (95% CI, 0.538 to 0.834) for an optimal cut-off of #
28 points (Figure 2). Using a cut-off value of #24 for MoCA
results, a total of 26 patients (59%) scored 24 points or lower,
while 18 patients achieved a higher score. Respectively, a PPV of
0.88 and NPV of 0.61 could be calculated for the patient cohort.
We identified 19 patients (46.3%) with a MMSE score of #
28 points.
Discussion
Here we demonstrate that the MoCA is a valid and well-suited
screening tool for cognitive impairment in HD patients. The
MoCA was capable of discriminating between HD patients with
and without cognitive impairment, as defined by performance on a
comprehensive neuropsychological test battery, presenting good
sensitivity and specificity levels, as well as a good concurrent
validity. In contrast, the MMSE revealed only a weak group
discriminative power.
Our main results confirm that the MoCA is able to reliably
identify cognitive impairment in CKD patients undergoing hemo-
dialysis. We could establish an optimal cut-off of#24 points out of a
30 points maximum, which is lower than the cut-off value of #26
described in the original data collected in a population of patients
with AD and mild cognitive impairment (MCI) [11]. Given that cut-
off values are population specific [39], several other studies have
determined lower values in different populations, e.g. a cut-off of
23.5 in a population with MCI [19] and of 21/22 in a population
with cerebral small vessel disease [17]. With a good sensitivity (76.67)
and specificity (78.57) our findings are consistent with previous
research, where the MoCA’s sensitivity in detecting cognitive
impairment ranged from 56% to 100%, while specificity varied
between 29% and 87%, depending on the study population
[11,18,40]. More specifically, in the detection of vascular cognitive
impairment the MoCA presented a specificity of 68% and lower
sensitivity of 56% in a population with silent cerebral infarction [40].
Figure 1. Group differences in cognitive domain composite scores of the Montreal Cognitive Assessment. The bar chart in figure 1
displays the average points scored by the patient and control group for each of the cognitive domains of the Montreal Cognitive Assessment (MoCA).
The group differences were assessed using the non-parametric Mann-Whitney-U test with respective p-values showing a significantly (p#.001) poorer
performance of the patient group in the domains of executive functions, episodic memory and language. Notes. *Executive: Trail Making Test (TMT)
B, verbal abstraction, digit span backwards, phonemic word fluency; Visuospatial: cube copying, clock drawing; Memory: immediate and delayed
word recall; Attention: digit span forwards, letter cancelation, number subtraction; Language: sentence repetition, animal naming; Orientation:
temporal and spatial orientation. Group differences were assessed using the Mann-Whitney-U test with a significance level of p#.001.
doi:10.1371/journal.pone.0106700.g001
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The detailed cognitive assessment showed a distinct difference
in achievement between groups. This tendency was equally
present in the MoCA results, whereas performance did not differ
between groups for the MMSE. The prevalence of cognitive
impairment of 70% in this cohort, as classified by the testing
battery, corresponds to the levels of cognitive dysfunction stated in
Table 2. Neuropsychological test results.
Neuropsychological domain/test Test results Mann-Whitney-U
N Patients N Controls p Effect size r
Screening tests
Montreal Cognitive Assessment (MoCA) 43 24.0 (4.0) 42 28.0 (3.0) ,.001* 2.573
Mini Mental State Examination (MMSE) 41 29.0 (2.0) 41 29.0 (2.0) .03 2.247
Attention
Test of attentional performance (TAP)
TAP Phasic Alertness 35 276.0 (73.0) 39 243.0 (60.0) .03 2.262
TAP Intrinsic Alertness 35 273.0 (51.0) 39 255.0 (64.0) .01 2.301
Digit span forwards 41 7.0 (2.0) 42 8.0 (4.0) .002 2.338
Verbal Memory
California Verbal Learning Test (CVLT)
CVLT Total learned 37 50.0 (16.0) 42 61.0 (15.0) ,.001* 2.415
CVLT Interference 37 5.0 (4.0) 42 6.0 (3.0) .04 2.232
CVLT Immediate Recall 37 9.0 (6.0) 42 12.5 (6.0) .002 2.327
CVLT Delayed Recall 37 11.0 (6.0) 42 12.5 (4.0) .002 2.341
CVLT Recognition (correct) 37 16.0 (2.0) 42 16.0 (1.0) .60 2.059
Non-verbal Memory
Medical College of Georgia Complex Figures (MCGCF)
MCGCF Immediate Recall 36 17.8 (12.4) 42 28.0 (13.5) .004 2.325
MCGCF Delayed Recall 36 16.5 (12.6) 41 28.0 (13.5) .008 2.266
Visuospatial
MCGCF Copy 36 31.5 (8.5) 42 34.0 (2.0) .02 2.264
Visual Object Space Perception (VOSP) Incomplete letters 40 20.0 (1.0) 42 20.0 (1.0) .39 2.095
Language
Boston Naming Test 39 15.0 (0.0) 42 15.0 (0.0) .06 2.207
Executive
Semantic word fluency 39 28.0 (17.0) 42 39.5 (12) ,.001* 2.409
Phonemic word fluency 39 14.0 (9.0) 42 21.0 (10.0) ,.001* 2.492
Digit span backwards 41 6.0 (2.0) 42 6.0 (1.0) .25 2.126
Stroop Test
Colour reading 33 35.0 (14.0) 41 32.0 (6.0) .01 2.288
Colour naming 33 54.0 (17.0) 41 47.0 (12.0) .01 2.285
Inteference 33 96.0 (49.0) 41 86.0 (28.0) .02 2.269
Trail Making Test (TMT) Part A 39 51.0 (38.0) 42 32.5 (15.0) ,.001* 2.512
Trail Making Test (TMT) Part B 38 110.5 (96.0) 42 73.5 (37.0) ,.001* 2.427
Depression
Hospital Anxiety and Depression Scale (HADS)
Total score 42 11.0 (9.0) 42 4.5 (7.0) ,.001* 2.373
Anxiety 42 6.0 (5.0) 42 3.0 (5.0) .02 2.266
Depression 42 4.5 (5.0) 42 1.0 (4.0) ,.001* 2.428
Fatigue
Epworth Sleepiness Scale (ESS) 42 6.5 (5.0) 42 5.5 (5.0) .05 2.217
Fatigue 21 5.0 (5.0) 34 2.0 (4.0) .02 2.318
Notes. Test results presented as median (IQR).
*p-values with Bonferroni correction for multiple comparisons.
Significant difference at p,.001. Effect sizes, r: small (0.10–0.29), medium (0.30–0.49), large (.0.50).
doi:10.1371/journal.pone.0106700.t002
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previous studies with larger cohorts of dialysis patients [5,7]. The
results presented by the MMSE equally match previous charac-
terizations of CKD patient cohorts, where the level of cognitive
dysfunction was measured at 30% when only using the MMSE as
a diagnostic measure [4,6]. The prevalence of cognitive dysfunc-
tion in this patient cohort appears, therefore, to be similar to
previous findings and allows the assumption that it is represen-
tative for this population. Correlation analysis showed a strong
relationship between MoCA results and the detailed neuropsy-
chological testing, especially for memory and executive functions,
which may suggest good diagnostic ability in these areas. There
remains, nevertheless, a limitation for interpretation of correlation
between tests, due to a partial overlap between tasks that may
affect association analysis.
The profile of cognitive deficits found in our patient population,
including significant impairment in executive functions, processing
speed, word fluency and short-term verbal and non-verbal
memory capacity, stands in accordance to previous findings
[3,41] and similar results have been associated with vascular
disease as a potential cause of cognitive impairment in HD
patients [15,42]. Given the high prevalence of executive dysfunc-
tion in CKD patients and our findings that performance in the
MoCA was predominantly dependent on executive ability (as has
been described before [43]), we believe that this is one of the
strengths of the MoCA in comparison to other generally used
cognitive screening instruments. In this regard, the focus of the
MoCA on executive functions is believed to be a reason why it is
far superior to the MMSE in particular clinical populations, given
that the MMSE lacks the assessment of such cognitive domains
and has a tendency to produce ceiling effects [43,44].
This may be particularly important considering that the
majority of previous studies with CKD patients have included
the MMSE as the preferred cognitive screening test [42] or even
the only cognitive instrument [45,46]. Methodologically, the fact
that the MoCA and the MMSE subtests partially overlap may
limit considerations of their differential discriminant validity, but it
should be noted that the original rationale behind MoCA, through
the inclusion of a wider range of cognitive domains than the
MMSE, especially considering the executive functions, already
entails some advantage in terms of sensitivity and specificity.
Based on our current results, and as others have suggested [8],
the MMSE may be inadequate for this population and may
underestimate the extent of cognitive impairment. Nevertheless, a
recent study showed that the MMSE was able to detect
progression of cognitive impairment in HD patients [47], but
may be less suited for early detection of mild cognitive deficits in
other populations [48]. In a similar fashion, another screening test,
the Kidney Disease Quality of Life Cognitive Function (KDQOL-
CF), was found to be inadequate for assessing cognitive function in
HD patients, due particularly to the lack of executive tasks [49].
A procedural advantage of the MoCA over the MMSE may also
be the availability of alternative versions [25], which enables
longitudinal testing while avoiding practice effects. Longitudinal
testing is especially interesting in HD patients, as fluctuations in
cognitive performance during the hemodialysis cycle have been
identified [20,50].
Concerning predictive clinical variables, we were able to show
that high comorbidity rates were associated with lower perfor-
mance on the MoCA, which opens the question of the etiological
Table 3. Criterion (cut-off) values and coordinates of the ROC curves of MoCA and MMSE.
Screening test Criterion Sensitivity 95% CI Specificity 95% CI
MoCA #22 46.67 28.3–65.7 78.57 49.2–95.3
#24* 76.67 57.7–90.1 78.57 49.2–95.3
#25 86.67 69.3–96.2 57.14 28.9–82.3
#26 90.00 73.5–97.9 35.71 12.8–64.9
MMSE #27 37.93 20.7–57.7 83.33 51.6–97.9
#28* 55.17 35.7–73.6 75.00 42.8–94.5
#29 89.66 72.6–97.8 33.33 9.9–65.1
Note:
*optimal cut-off score based on maximal sensitivity and specificity using the receiver operating characteristic (ROC) analysis.
doi:10.1371/journal.pone.0106700.t003
Figure 2. ROC curves for the cognitive screening tests Montreal
Cognitive Assessment and Mini-Mental State Examination. The
receiver operating characteristics curves for the Montreal Cognitive
Assessment (MoCA) and the Mini-Mental State Examination (MMSE)
illustrate the discriminative capacity of each of the screening tests,
displaying their individual sensitivity, specificity and area under the
curve (AUC). The MoCA shows good levels of sensitivity and specificity,
as well as an overall greater AUC than the MMSE, while the MMSE
presents a high specificity and relatively low sensitivity. Notes.
MoCA=Montreal Cognitive Assessment; MMSE =Mini-Mental State
Examination; AUC=Area under the curve.
doi:10.1371/journal.pone.0106700.g002
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or mediator role that different comorbidities play in cognitive
impairment in such a heterogeneous group.
Other interesting findings were that although levels of fatigue
and sleepiness were higher in the patient group, which is in line
with statements from earlier studies that fatigue is a common
problem in HD patients [3,51], we did not find fatigue or
sleepiness to influence cognitive performance. It is possible that
conducting the assessment on a dialysis-free day avoided post-
dialytic fatigue and enabled a more objective assessment of
cognitive performance. In contrast, a significant association was
found between lower performance and higher levels of depressive
symptoms, which supports assumptions that depression may be a
relevant co-factor for poor cognitive performance and should also
be screened for in CKD patients [52–54]. This is especially
important when taking into account the prevalence of depression
of up to 25% in HD patients [51] and the number of associated
problems, including lower quality of life and higher hospitalization
and mortality rates [54].
Further strengths of our study include the detailed neuropsy-
chological testing, which enabled a comprehensive evaluation of
cognition and the interpretation of concurrent validity, as well as
the inclusion of a healthy control group that served as reference for
cognitive performance. The MoCA has recently been suggested
for cognitive screening in a small cohort of HD patients showing
similar results for MoCA with an average of 24 points before
dialysis [20], yet the emphasis was put on testing environment and
variation in performance during the HD cycle and only the
MMSE was used as a reference. This is therefore a valuable
addition, as there is no precedent data on the psychometric
characteristics of MoCA in comparison to detailed cognitive
analysis and clinical characterization of a moderate size sample of
HD patients. Limitations are, nevertheless, the relatively small
sample size, which makes it difficult to generalize our findings.
Although our results allow the assumption of cognitive impairment
in HD patients below the cut-off value of 24 points in the MoCA,
a clear distinction between MCI and dementia cannot be made in
this study, due to the exclusion of patients with dementia. Equally,
one must mention again the concordance of tests used in the
screening tests and the detailed test battery that may influence
correlation analyses in form of a positive bias. Our decision to
enter education as a covariate rather than using the education
correction for MoCA values, for which there is no normative data
for a German population, may be seen as inadequate as there is a
slight difference in educational levels between groups. Further-
more, data on subjective cognitive impairment, and clinical data
were limited, the latter especially for the control sample, reducing
our ability to assess variables, such as cardiovascular risk factors
and hemodialysis parameters, in more detail. Further research is
warranted to confirm these findings in a larger patient sample,
possibly including non-dialysis CKD patients to further define
indications for cognitive screening with the MoCA.
Cognitive impairment is a highly relevant clinical factor for
disease progression in HD patients, possibly also affecting daily-life
activities, thereby impeding adherence to therapeutic regimes and
compromising quality of life. With the aims of improvement of
individual outcome and optimizing the utilization of medical care
resources, a brief cognitive screening test for HD patients is an
essential addition to clinical practice. We presume that the MoCA,
granted its validity and psychometric characteristics, is very
suitable for this purpose, as it represents a multi-dimensional
screening test that not only includes relevant tasks for the
assessment of the HD population, but also offers the possibility
of longitudinal measurements with available alternate versions.
In conclusion, the MoCA is an adequate screening tool for a
brief bedside evaluation of global cognitive performance in HD
patients and has the potential to assist in the daily clinical care of
HD patients.
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